Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

461
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
461
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

445
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
445
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

515
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
515
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

486
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
486
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

723
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
723
Glucose Transporters01:27

Glucose Transporters

27.0K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electrochemical in-biosensing computing.

National science review·2026
Same author

Downregulation of PCAF inhibits vascular smooth muscle cells senescence by reducing oxidative stress injury via activating the Nrf2/ARE pathway.

Clinical hemorheology and microcirculation·2026
Same author

A regional framework for defining and translating healthy dietary patterns in China.

NPJ science of food·2026
Same author

A bioinspired photoelectrochemical synapse for neurotransmitter-mediated in-sensor computing.

Biosensors & bioelectronics·2026
Same author

Synergistic enhancement of microalgal fatty acids via Batch Bayesian Optimization-driven combinatorial additive engineering.

Bioresource technology·2026
Same author

Dynamic characterization of humidity-induced perovskite/polyacrylonitrile composite nanofibers based on tilted fiber grating.

Optics express·2026
Same journal

Opportunistic screening for incident cardiometabolic disease in metabolically healthy non-obese individuals: a prospective cohort study.

Cardiovascular diabetology·2026
Same journal

Insulin resistance surrogate indices and incident cardiovascular disease across cardiovascular-kidney-metabolic stages 0-3: a prospective cohort study.

Cardiovascular diabetology·2026
Same journal

Deep learning analysis of ECGs detects Cardiovascular-Kidney-Metabolic syndrome burden in people with diabetes: a report from the Silesia Diabetes-Heart Project.

Cardiovascular diabetology·2026
Same journal

Association of the atherogenic index of plasma and its integrative novel adiposity-based composites with all-cause and cardiovascular mortality in individuals with cardiovascular-kidney-metabolic syndrome: novel adiposity-derived AIP indices provide modest incremental prognostic information.

Cardiovascular diabetology·2026
Same journal

Correlation between surrogate indicators of insulin resistance and all-cause mortality in patients with severe hemorrhagic stroke: a multicenter retrospective cohort study in the United States.

Cardiovascular diabetology·2026
Same journal

Integrating lipometabolic and adiposity indices to enhance risk stratification for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: clinical utility and interplay between triglyceride-glucose body mass index and low-density lipoprotein cholesterol.

Cardiovascular diabetology·2026
See all related articles

Related Experiment Video

Updated: Dec 17, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.6K

SGLT2i: beyond the glucose-lowering effect.

Lihua Ni1, Cheng Yuan2, Guopeng Chen3,4

  • 1Department of Nephrology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei, 430071, China.

Cardiovascular Diabetology
|June 28, 2020
PubMed
Summary
This summary is machine-generated.

Sodium/glucose cotransporter-2 inhibitors (SGLT2i) offer new hope for type 2 diabetes patients. These drugs lower blood glucose and provide significant heart and kidney protection, improving patient quality of life.

Keywords:
Cardiovascular diseaseRenal diseaseSodium-glucose cotransporter-2 inhibitors (SGLT2i)Type 2 diabetes

More Related Videos

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

20.5K
Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

3.1K

Related Experiment Videos

Last Updated: Dec 17, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.6K
Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

20.5K
Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

3.1K

Area of Science:

  • Pharmacology
  • Nephrology
  • Cardiology

Background:

  • Sodium/glucose cotransporter-2 inhibitors (SGLT2i) are a novel class of glucose-lowering agents.
  • Widely used for type 2 diabetes mellitus (T2DM) management.
  • Emerging evidence highlights SGLT2i's cardioprotective and renoprotective effects beyond glycemic control.

Purpose of the Study:

  • To review the historical development and pharmacological mechanisms of SGLT2i.
  • To elucidate the cardio- and renoprotective benefits of SGLT2i in T2DM.
  • To provide a comprehensive overview of SGLT2i safety profiles.

Main Methods:

  • Literature review of SGLT2i studies.
  • Analysis of pharmacological mechanisms.
  • Synthesis of clinical trial data on cardiovascular and renal outcomes.
  • Review of safety data.

Main Results:

  • SGLT2i reduce blood glucose by inhibiting proximal tubule reabsorption and promoting urinary glucose excretion.
  • SGLT2i significantly decrease cardiovascular events and delay renal failure progression.
  • These agents improve patient quality of life and reduce healthcare costs.

Conclusions:

  • SGLT2i offer multifaceted benefits for T2DM patients, including glycemic control and organ protection.
  • Understanding SGLT2i mechanisms is crucial for managing diabetes complications.
  • SGLT2i represent a valuable therapeutic option for preventing adverse cardiac and renal events in T2DM.